The patient perspective: Quality of life in advanced heart failure with frequent hospitalisations

Abstract

End of life is an unfortunate but inevitable phase of the heart failure patients' journey. It is often preceded by a stage in the progression of heart failure defined as advanced heart failure, and characterised by poor quality of life and frequent hospitalisations. In clinical practice, the efficacy of treatments for advanced heart failure is often assessed by parameters such as clinical status, haemodynamics, neurohormonal status, and echo/MRI indices. From the patients' perspective, however, quality-of-life-related parameters, such as functional capacity, exercise performance, psychological status, and frequency of re-hospitalisations, are more significant. The effects of therapies and interventions on these parameters are, however, underrepresented in clinical trials targeted to assess advanced heart failure treatment efficacy, and data are overall scarce. This is possibly due to a non-universal definition of the quality-of-life-related endpoints, and to the difficult standardisation of the data collection. These uncertainties also lead to difficulties in handling trade-off decisions between quality of life and survival by patients, families and healthcare providers. A panel of 34 experts in the field of cardiology and intensive cardiac care from 21 countries around the world convened for reviewing the existing data on quality-of-life in patients with advanced heart failure, discussing and reaching a consensus on the validity and significance of quality-of-life assessment methods. Gaps in routine care and research, which should be addressed, were identified. Finally, published data on the effects of current i.v. vasoactive therapies such as inotropes, inodilators, and vasodilators on quality-of-life in advanced heart failure patients were analysed.

Budget impact of intravenous iron therapy with ferric carboxymaltose in patients with chronic heart failure and iron deficiency in Germany

“…Symptoms (breathlessness, fatigue, and fluid retention) appear slowly and worsen over time,1, 2 which leads to a significant impact on patient's quality of life 3, 4, 5…”

Pharmaco-economics of levosimendan in cardiology: A European perspective

“…Levosimendan (gray), dobutamine (black). improvement in patient Quality of Life [25] and a reduction in patient mortality [14], which provides even stronger support for the rationale of using the drug.…”

Galectina-3: experiencia en pacientes chilenos con diagnóstico de insuficiencia cardíaca descompensada

“…Como es posible esperar en pacientes con este perfil de severidad, se observó un alto porcentaje de pacientes con hospitalizaciones previas. Particularmente importante es la elevada prevalencia de síntomas depresivos y la baja calidad de vida autoreportada, la que es marcadamente peor a la observada en otros estudios que evalúan población de pacientes hospitalizados [14][15][16][17] . Una explicación posible de estos hallazgos puede ser la prevalencia de fragilidad concomitante en nuestra población, comparable con la de otros estudios 18 , la cual se presenta en pacientes con síntomas depresivos y, además, disminuye la calidad de vida, sin embargo, la implicancia de estos hallazgos debe ser analizada en futuros estudios.…”